CD8A and cancer: We observed a shift in the T-cell population from naïve to central memory CD4+ and CD8+ T cells following stimulation of serum-derived EVs (in healthy and cancer patients), providing evidence of initial activation of T cells following EV antigen presentation in vitro. Cancer-derived EVs have been reported to escape immune surveillance by mechanisms that are numerous and varied (40–43).